Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation.

Authors: R J Bluett, J C Gamble-George, D J Hermanson, N D Hartley, L J Marnett, S Patel
Translational Psychiatry, 8 July 2014

Stress is a major risk factor for the development of mood and anxiety disorders; elucidation of novel approaches to mitigate the deleterious effects of stress could have broad clinical applications. Pharmacological augmentation of central endogenous cannabinoid (eCB) signaling…

Genetic variations in the human cannabinoid receptor gene are associated with happiness.

Authors: Masahiro Matsunaga , Tokiko Isowa, Kaori Yamakawa, Seisuke Fukuyama, Jun Shinoda, et al
PLoS One, 1 April 2014

Happiness has been viewed as a temporary emotional state (e.g., pleasure) and a relatively stable state of being happy (subjective happiness level). As previous studies demonstrated that individuals with high subjective happiness level rated their current affective states more…

The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD).

Post-traumatic stress disorder (PTSD) is a psychiatric disorder of significant prevalence and morbidity, whose pathogenesis relies on paradoxical changes of emotional memory processing. An ideal treatment would be a drug able to block the pathological over-consolidation and continuous retrieval of the traumatic event, while enhancing its extinction and reducing the anxiety symptoms.

Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.

Authors: Torsten Passie, Hinderk M. Emrich, Matthias Karst, Simon D. Brandt, John H. Halpern
Drug Testing and Analysis, July-August 2012

It is known from clinical studies that some patients attempt to cope with the symptoms of post-traumatic stress disorder (PTSD) by using recreational drugs. This review presents a case report of a 19-year-old male patient with a spectrum of severe PTSD symptoms, such as intens…

Prescribing cannabis for harm reduction.

Authors: Mark Collen
Harm Reduction Journal, 1 January 2012

Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without…

Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.

Authors: Celia J.A. Morgan, Tom P. Freeman, Gráinne L. Schafer, H. Valerie Curran
Neuropsychopharmacology, August 2010

Worldwide cannabis dependence is increasing, as is the concentration of Delta(9)-tetrahydrocannabinol (THC) in street cannabis. At the same time, the concentration of the second most abundant cannabinoid in street cannabis, cannabidiol (CBD), is decreasing. These two cannabino…

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.

Authors: A. W. Zuardi, I. Shirakawa, E. Finkelfarb, I. G. Karniol
Psychopharmacology, DATE

The object of the experiment was to verify whether cannabidiol (CBD) reduces the anxiety provoked by delta 9-THC in normal volunteers, and whether this effect occurs by a general block of the action of delta 9-THC or by a specific anxiolytic effect. Appropriate measurements an…